Avalon GloboCare Corp. (ALBT)
ALBT Stock Price Chart
Explore Avalon GloboCare Corp. interactive price chart. Choose custom timeframes to analyze ALBT price movements and trends.
ALBT Company Profile
Discover essential business fundamentals and corporate details for Avalon GloboCare Corp. (ALBT) to support your stock research and investment decisions.
Sector
Real Estate
Industry
Real Estate - Services
IPO Date
27 Mar 2018
Employees
4.00
Website
https://www.avalon-globocare.comCEO
Meng Li
Description
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
ALBT Financial Timeline
Browse a chronological timeline of Avalon GloboCare Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 11 May 2026
EPS came in at -$0.49 .
Earnings released on 13 Feb 2026
EPS came in at -$0.43 , while revenue for the quarter reached -$1.05m .
Earnings released on 14 Nov 2025
EPS came in at -$0.06 , while revenue for the quarter reached $350.10k .
Earnings released on 14 Aug 2025
EPS came in at -$2.02 , while revenue for the quarter reached $350.41k .
Earnings released on 13 May 2025
EPS came in at -$1.43 , while revenue for the quarter reached $349.80k .
Earnings released on 31 Mar 2025
EPS came in at -$1.99 , while revenue for the quarter reached $345.77k .
Earnings released on 12 Nov 2024
EPS came in at -$1.82 , while revenue for the quarter reached $345.16k .
Stock split effective on 28 Oct 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Aug 2024
EPS came in at -$2.85 , while revenue for the quarter reached $327.89k .
Earnings released on 30 May 2024
EPS came in at -$1.80 , while revenue for the quarter reached $314.59k .
Earnings released on 15 Apr 2024
EPS came in at -$13.49 , while revenue for the quarter reached $321.32k .
Earnings released on 14 Nov 2023
EPS came in at -$2.10 , while revenue for the quarter reached $331.29k .
Earnings released on 14 Aug 2023
EPS came in at -$3.75 , while revenue for the quarter reached $306.91k .
Earnings released on 22 May 2023
EPS came in at -$4.20 , while revenue for the quarter reached $296.17k .
Earnings released on 30 Mar 2023
EPS came in at -$0.30 , while revenue for the quarter reached $296.33k .
Stock split effective on 5 Jan 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$9.00 , while revenue for the quarter reached $317.39k .
Earnings released on 30 Jun 2022
EPS came in at -$0.29 , while revenue for the quarter reached $290.82k .
Earnings released on 31 Mar 2022
EPS came in at -$0.23 , while revenue for the quarter reached $297.63k .
Earnings released on 31 Dec 2021
EPS came in at -$0.27 , while revenue for the quarter reached $334.20k .
Earnings released on 30 Sept 2021
EPS came in at -$0.24 , while revenue for the quarter reached $486.76k .
ALBT Stock Performance
Access detailed ALBT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
